ClinicalTrials.gg
TerminatedNCT03616912SLE-BRAVE IUpdated Jan 30, 2023Results posted

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

A Phase 3 interventional study of Baricitinib and Placebo in Systemic Lupus Erythematosus, sponsored by Eli Lilly and Company. Terminated at 184 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-30.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Why this study was terminated
Study terminated due to insufficient evidence to support a positive benefit: risk profile in systemic lupus erythematosus patients.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
830
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Lupus Erythematosus, Systemic · Eli Lilly and Company.

Enrollment
5th of 11
830 · median 778
Started
2018
with 1 other
Phase 3
7 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, this one is the 5th largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 6th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

1 of the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, or all of them as a file.
02

Study summary

The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • SLE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a clinical diagnosis of SLE at least 24 weeks prior to screening.
  • Have documentation of having met at least 4 of 11 Revised Criteria for Classification of Systemic Lupus Erythematosus according to the 1997 Update of the 1982 American College of Rheumatology (ACR) criteria for classification of SLE prior to randomization.
  • Have a positive antinuclear antibody (ANA) (titer ≥1:80) and/or a positive anti-double-stranded deoxyribonucleic acid (dsDNA), and/or a positive anti-Smith (anti-Sm) as assessed by a central laboratory during screening.
  • Have a total Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥6 during screening.
  • Have a clinical SLEDAI-2K score ≥4 at randomization.
  • Have at least 1 British Isles Lupus Assessment Group (BILAG) A score or 2 BILAG B scores during screening.
  • Are receiving at least one of the following standard of care medications for SLE:

    • A single antimalarial at a stable dose for at least 8 weeks prior to screening
    • A single at a stable dose for at least 8 weeks prior to screening
    • An oral , initiated at least 4 weeks prior to screening, at a stable dose ≤40 milligrams/day prednisone (or equivalent) for at least 2 weeks prior to screening. If the participant is not receiving an antimalarial or immunosuppressant, the dose of corticosteroid must be ≥7.5 milligrams/day prednisone (or equivalent)

Exclusion criteria

Exclusion Criteria:

  • Have severe active lupus nephritis.
  • Have active central nervous system (CNS) lupus.
  • Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking product or interfere with the interpretation of data.
  • Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection.
  • Have received cyclophosphamide (or any other cytotoxic agent) within 12 weeks prior to screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
830 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received two placebo tablets: one matching baricitinib 4 milligram (mg) and one matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.

    Drug: Placebo

  • Experimental
    2 mg Baricitinib

    Participants received one Baricitinib 2 mg tablet and one placebo tablet matching Baricitinib 4 mg administered QD for 52 weeks.

    Drug: Baricitinib · Drug: Placebo

  • Experimental
    4 mg Baricitinib

    Participants received one Baricitinib 4 mg tablet and one placebo tablet matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.

    Drug: Baricitinib · Drug: Placebo

  • Placebo comparator
    Placebo Maximum Extended Enrollment (MEE)

    Participants received two placebo tablets: one matching baricitinib 4 mg and one matching baricitinib 2 mg administered orally QD for 52 weeks.

    Drug: Placebo

  • Experimental
    2 mg Baricitinib (MEE)

    Participants received one Baricitinib 2 mg tablet and 1 placebo tablet matching Baricitinib 4 mg administered QD for 52 weeks.

    Drug: Baricitinib · Drug: Placebo

  • Experimental
    4 mg Baricitinib (MEE)

    Participants received one Baricitinib 4 mg tablet and one placebo tablet matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.

    Drug: Baricitinib · Drug: Placebo

Interventions

  • Administered orally.

    Also known as: LY3009104

  • DrugPlacebo

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib)

    SRI-4 response defined as 1)greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of \>=0.3 from baseline on a 0-3 visual analogue scale). SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Achieving SRI-4 Response - 2 mg Baricitinib

    SRI-4 response defined as 1)greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of \>=0.3 from baseline on a 0-3 visual analogue scale). SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).

    Time frame: Week 52

  2. Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)

    The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K \<=4, with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where "no activity" is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the "new feature" is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), \<=1; (4) current prednisolone (or equivalent) dose \<=7.5 mg daily.

    Time frame: Week 52

  3. Time to First Severe Flare

    Time to first severe flare was analyzed using a Cox proportional hazards model with treatment group, baseline disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000 \[SLEDAI-2K \] \<10; SLEDAI-2K ≥10), baseline corticosteroid dose (\<10 mg/day; ≥10 mg/day prednisone or equivalent), and region fitted as explanatory variables. Participants who did not have severe flare during the flare exposure time period were censored at the end of the flare exposure time.

    Time frame: Baseline to Week 52

  4. Percentage of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Participants Receiving Greater Than 7.5 mg/Day at Baseline

    For the analysis of steroid use, steroid dosages were converted to a prednisone equivalent in mg. A responder was defined as having a prednisone reduction by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52.

    Time frame: Baseline, Week 40 through Week 52

  5. Change From Baseline in Worst Pain Numeric Rating Scale (NRS)

    Participants assessed their worst pain in the last 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The average worst daily pain score was calculated as the mean of the scores over the last 7 days prior to each assessment time point. Higher score indicated severe pain. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

    Time frame: Baseline, Week 52

  6. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total Score

    FACIT-Fatigue score calculated according to a 13-item questionnaire that assess self reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

    Time frame: Baseline, Week 52

  7. Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score

    The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations.

    Time frame: Week 52

  8. Change From Baseline in Tender Joints Count

    The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

    Time frame: Baseline, Week 52

  9. Change From Baseline in Swollen Joint Count

    The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

    Time frame: Baseline, Week 52

  10. Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss)

    PK: Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss) was evaluated using population PK approach.

    Time frame: Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose

  11. Population PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss)

    Population PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss) was evaluated using population PK approach.

    Time frame: Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose

07

Results

Posted Jan 30, 2023
Limitations and caveats
One investigational site with seven participants was excluded from analysis due to confirmed misconduct. Study terminated due to insufficient evidence to support a positive benefit: risk profile in systemic lupus erythematosus patients.

Participant flow

Participant flow — Overall Study
MilestonePlacebo2 mg Baricitinib4 mg BaricitinibPlacebo (MEE)2 mg Baricitinib (MEE)4 mg Baricitinib (MEE)
Started257258254212020
Received at least one dose of study drug257256254212020
Excluded due to site misconduct412000
Completed204211208556
Not completed534746161514
Withdrew: Adverse event17219000
Withdrew: Death110000
Withdrew: Lack of efficacy1368451
Withdrew: Lost to follow-up123000
Withdrew: Due to epidemic/pandemic425000
Withdrew: Withdrawal by subject121215202
Withdrew: Study terminated by sponsor00010911
Withdrew: Protocol deviation110000
Withdrew: Pregnancy104000
Withdrew: Protocol violation102000
Withdrew: Physician decision200010
Withdrew: Randomized but never treated020000

Outcome measures

PrimaryPercentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib)

SRI-4 response defined as 1)greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of \>=0.3 from baseline on a 0-3 visual analogue scale). SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib)
percentage of participantsPlacebo4 mg Baricitinib
Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib)45.956.7
Statistical analysis
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.016 · Odds ratio (or): 1.57 · 95% CI 1.09 to 2.27
SecondaryPercentage of Participants Achieving SRI-4 Response - 2 mg Baricitinib

SRI-4 response defined as 1)greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of \>=0.3 from baseline on a 0-3 visual analogue scale). SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SRI-4 Response - 2 mg Baricitinib
percentage of participantsPlacebo2 mg Baricitinib
Percentage of Participants Achieving SRI-4 Response - 2 mg Baricitinib45.949.8
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.470 · Odds ratio (or): 1.14 · 95% CI 0.79 to 1.65
SecondaryPercentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)

The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K \<=4, with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where "no activity" is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the "new feature" is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), \<=1; (4) current prednisolone (or equivalent) dose \<=7.5 mg daily.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)26.225.729.7
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.839 · Odds ratio (or): 0.96 · 95% CI 0.63 to 1.45
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.391 · Odds ratio (or): 1.19 · 95% CI 0.80 to 1.79
SecondaryTime to First Severe Flare

Time to first severe flare was analyzed using a Cox proportional hazards model with treatment group, baseline disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000 \[SLEDAI-2K \] \<10; SLEDAI-2K ≥10), baseline corticosteroid dose (\<10 mg/day; ≥10 mg/day prednisone or equivalent), and region fitted as explanatory variables. Participants who did not have severe flare during the flare exposure time period were censored at the end of the flare exposure time.

Time frame:
Baseline to Week 52
Reported as:
Median · weeks
Time to First Severe Flare
weeksPlacebo2 mg Baricitinib4 mg Baricitinib
Time to First Severe FlareNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Participants Receiving Greater Than 7.5 mg/Day at Baseline

For the analysis of steroid use, steroid dosages were converted to a prednisone equivalent in mg. A responder was defined as having a prednisone reduction by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52.

Time frame:
Baseline, Week 40 through Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Participants Receiving Greater Than 7.5 mg/Day at Baseline
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Participants Receiving Greater Than 7.5 mg/Day at Baseline30.829.234.0
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.820 · Odds ratio (or): 0.94 · 95% CI 0.53 to 1.66
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.565 · Odds ratio (or): 1.18 · 95% CI 0.67 to 2.08
SecondaryChange From Baseline in Worst Pain Numeric Rating Scale (NRS)

Participants assessed their worst pain in the last 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The average worst daily pain score was calculated as the mean of the scores over the last 7 days prior to each assessment time point. Higher score indicated severe pain. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Worst Pain Numeric Rating Scale (NRS)
score on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in Worst Pain Numeric Rating Scale (NRS)-1.62 ± 0.15-1.73 ± 0.15-1.71 ± 0.15
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.598 · Ls mean difference final values: -0.11 · 95% CI -0.52 to 0.30
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.674 · Ls mean difference final values: -0.09 · 95% CI -0.50 to 0.32
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total Score

FACIT-Fatigue score calculated according to a 13-item questionnaire that assess self reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total Score
score on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total Score7.44 ± 0.627.46 ± 0.607.08 ± 0.61
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.979 · Ls mean difference final values: 0.02 · 95% CI -1.65 to 1.70
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.678 · Ls mean difference final values: -0.36 · 95% CI -2.03 to 1.32
SecondaryPercentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score

The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score49.054.355.8
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.965 · Odds ratio (or): 1.02 · 95% CI 0.43 to 2.42
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.661 · Odds ratio (or): 1.22 · 95% CI 0.51 to 2.92
SecondaryChange From Baseline in Tender Joints Count

The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · tender joint count
Change From Baseline in Tender Joints Count
tender joint countPlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in Tender Joints Count-7.50 ± 0.312-7.26 ± 0.305-7.94 ± 0.307
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.578 · Ls mean difference final values: 0.24 · 95% CI -0.61 to 1.08
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.309 · Ls mean difference final values: -0.44 · 95% CI -1.29 to 0.41
SecondaryChange From Baseline in Swollen Joint Count

The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · swollen joint count
Change From Baseline in Swollen Joint Count
swollen joint countPlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in Swollen Joint Count-5.37 ± 0.201-5.67 ± 0.196-5.81 ± 0.198
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.287 · Ls mean difference final values: -0.29 · 95% CI -0.84 to 0.25
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.113 · Ls mean difference final values: -0.44 · 95% CI -0.99 to 0.11
SecondaryPopulation Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss)

PK: Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss) was evaluated using population PK approach.

Time frame:
Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss)
hour*nanograms per milliliter (h*ng/mL)2 mg Baricitinib4 mg Baricitinib
Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss)256 ± 52502 ± 52
SecondaryPopulation PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss)

Population PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss) was evaluated using population PK approach.

Time frame:
Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Population PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss)
nanograms per milliliter (ng/mL)2 mg Baricitinib4 mg Baricitinib
Population PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss)26.7 ± 2453.0 ± 23

Adverse events

Collected over Baseline through Follow-up (Up to 56 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/253 (0.4%)19/253 (7.5%)129/253 (51%)
2 mg Baricitinib1/255 (0.4%)27/255 (10.6%)144/255 (56.5%)
4 mg Baricitinib0/252 (0%)31/252 (12.3%)144/252 (57.1%)
Placebo Maximum Extended Enrollment (MEE)0/21 (0%)1/21 (4.8%)17/21 (81%)
2 mg Baricitinib (MEE)0/20 (0%)4/20 (20%)14/20 (70%)
4 mg Baricitinib (MEE)0/20 (0%)3/20 (15%)17/20 (85%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventPlacebo2 mg Baricitinib4 mg BaricitinibPlacebo Maximum Extended Enrollment (MEE)2 mg Baricitinib (MEE)4 mg Baricitinib (MEE)
Cholecystitis chronicHepatobiliary disorders0/2530/2550/2520/210/201/20
CholelithiasisHepatobiliary disorders0/2531/2550/2520/210/201/20
OsteonecrosisMusculoskeletal and connective tissue disorders0/2530/2550/2520/211/200/20
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders1/2531/2554/2520/211/201/20
Haemangioma of liverNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2530/2550/2520/211/200/20
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2370/2381/2370/200/191/20
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders0/2530/2550/2520/211/200/20
Lupus nephritisRenal and urinary disorders1/2532/2551/2521/210/200/20
PneumoniaInfections and infestations0/2534/2552/2520/210/200/20
Ankle fractureInjury, poisoning and procedural complications0/2530/2552/2520/210/200/20
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPlacebo2 mg Baricitinib4 mg BaricitinibPlacebo Maximum Extended Enrollment (MEE)2 mg Baricitinib (MEE)4 mg Baricitinib (MEE)
Upper respiratory tract infectionInfections and infestations17/25321/25519/2525/219/207/20
HypertriglyceridaemiaMetabolism and nutrition disorders4/2539/2553/2525/210/201/20
HyperlipidaemiaMetabolism and nutrition disorders1/2532/2556/2523/214/203/20
HyperuricaemiaMetabolism and nutrition disorders1/2532/2552/2522/213/204/20
Urinary tract infectionInfections and infestations25/25332/25537/2522/213/201/20
DizzinessNervous system disorders4/2531/2555/2520/211/203/20
AnaemiaBlood and lymphatic system disorders4/2534/25513/2523/212/202/20
LymphopeniaBlood and lymphatic system disorders10/25311/2559/2523/211/201/20
Iron deficiency anaemiaBlood and lymphatic system disorders0/2534/2550/2522/210/202/20
HypothyroidismEndocrine disorders1/2531/2550/2520/212/200/20

Baseline characteristics

All randomized participants who receive at least one dose of study drug. One investigational site with seven participants was excluded from analysis due to confirmed misconduct.

Age, Continuous
Age, Continuous(years)Placebo2 mg Baricitinib4 mg BaricitinibPlacebo Maximum Extended Enrollment (MEE)2 mg Baricitinib MEE4 mg Baricitinib MEETotal
Mean42.00 ± 11.9842.90 ± 12.4441.50 ± 12.8832.90 ± 10.8337.70 ± 11.3834.60 ± 8.3141.60 ± 12.43
Sex: Female, Male
Sex: Female, Male(Participants)Placebo2 mg Baricitinib4 mg BaricitinibPlacebo Maximum Extended Enrollment (MEE)2 mg Baricitinib MEE4 mg Baricitinib MEETotal
Female237238237201920771
Male16171511050
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo2 mg Baricitinib4 mg BaricitinibPlacebo Maximum Extended Enrollment (MEE)2 mg Baricitinib MEE4 mg Baricitinib MEETotal
Hispanic or Latino4131100028
Not Hispanic or Latino423538000115
Unknown or Not Reported207207203212020678
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo2 mg Baricitinib4 mg BaricitinibPlacebo Maximum Extended Enrollment (MEE)2 mg Baricitinib MEE4 mg Baricitinib MEETotal
American Indian or Alaska Native1215700034
Asian333934212020167
Native Hawaiian or Other Pacific Islander0000000
Black or African American36233000089
White168172177000517
More than one race1200003
Unknown or Not Reported34400011
Region of Enrollment
Region of Enrollment(Participants)Placebo2 mg Baricitinib4 mg BaricitinibPlacebo Maximum Extended Enrollment (MEE)2 mg Baricitinib MEE4 mg Baricitinib MEETotal
Australia1091200031
Austria0120003
Belgium2110004
Brazil38222300083
China162118212020116
Croatia53200010
Czechia1811900038
Germany14141700045
Greece49500018
Hungary13181900050
Israel1340008
Mexico365149000136
Netherlands0110002
Russia26252000071
Switzerland3230008
Taiwan15111300039
United Kingdom54400013
United States474950000146
08

Study locations

184 sites
  • Achieve Clinical Research, LLC
    Birmingham, Alabama 35216, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Glendale, Arizona 85306, United States
  • University of Arizona
    Tucson, Arizona 85711, United States
  • St. Joseph Heritage Medical Group
    Fullerton, California 92835, United States
  • MD Medical Corporation
    Hemet, California 92543, United States
  • ACRC Studies
    Poway, California 92064, United States
  • Office: Hans R Barthel M.D.
    Santa Barbara, California 93108, United States
  • Medvin Clinical Research - Weidmann
    Whittier, California 90602, United States
  • Denver Arthritis Clinic - Lowry
    Denver, Colorado 80230, United States
  • New England Research Associates
    Bridgeport, Connecticut 06606, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06519, United States
  • Arthritis and Rheumatic Disease
    Aventura, Florida 33180, United States
  • Rheumatology Associates of South Florida
    Boca Raton, Florida 33486, United States
  • Clinical Research of West Florida, Inc. (Clearwater)
    Clearwater, Florida 33765, United States
  • Arthritis and Rheumatology Center of South Florida
    Margate, Florida 33063, United States
  • Lakes Research, LLC
    Miami Lakes, Florida 33014, United States
  • Millennium Research
    Ormond Beach, Florida 32174, United States
  • IRIS Research and Development, LLC
    Plantation, Florida 33324, United States
  • ForCare Clinical Research
    Tampa, Florida 33613-1244, United States
  • Piedmont Healthcare
    Atlanta, Georgia 30318, United States
  • Atlanta Center for Clinical Research
    Atlanta, Georgia 30342, United States
  • St Luke's Clinic - Intermountain Orthopaedics
    Boise, Idaho 83702, United States
  • Rockford Orthopedic Associates
    Rockford, Illinois 61114, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Clinical Research Institute of Michigan, LLC
    Saint Clair Shores, Michigan 48081, United States
  • St. Louis Rheumatology
    Saint Louis, Missouri 63119, United States
  • Glacier View Research Institute - Endocrinology
    Kalispell, Montana 59901, United States
  • Allied Clinical Research
    Reno, Nevada 89519, United States
  • Albuquerque Center for Rheumatology
    Albuquerque, New Mexico 87102, United States
  • SUNY Health Science Center
    Brooklyn, New York 11203, United States
  • St. Lawrence Health System
    Canton, New York 13617, United States
  • Northwell Health
    Great Neck, New York 11021, United States
  • The Feinstein Institute for Medical Research
    Manhasset, New York 11030, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Buffalo Rheumatology
    Orchard Park, New York 14127, United States
  • Joint and Muscle Medical Care
    Charlotte, North Carolina 28204, United States
  • Medication Management, LLC
    Greensboro, North Carolina 27408, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Cincinnati Arthritis Associates
    Cincinnati, Ohio 45242, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Paramount Medical Research
    Middleburg Heights, Ohio 44130, United States
  • Arthritis & Rheumatology Center of Oklahoma PLLC
    Oklahoma City, Oklahoma 73102, United States
  • East Penn Rheumatology Associates
    Bethlehem, Pennsylvania 18015, United States
  • UPMC Lupus Center of Excellence
    Pittsburgh, Pennsylvania 15213, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Amarillo Center for Clinical Research
    Amarillo, Texas 79124, United States
  • Accurate Clinical Management
    Baytown, Texas 77521, United States
  • Dr. Dhiman Basu Private Practice
    Colleyville, Texas 76034, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Precision Comprehensive Clinical Research Solutions
    Fort Worth, Texas 76107, United States
  • Rheumatology Center of Houston
    Houston, Texas 77004, United States
  • Accurate Clinical Research
    Houston, Texas 77089, United States
  • Southwest Rheumatology, P.A.
    Mesquite, Texas 75150, United States
  • Accurate Clinical Research, Inc.
    San Antonio, Texas 78229, United States
  • Univ of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • Arthritis Clinic Of Central Texas
    San Marcos, Texas 78666, United States
  • Spectrum Medical Inc.
    Danville, Virginia 24541, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • Rheumatic Disease Center
    Glendale, Wisconsin 53217, United States
  • Emeritus Research
    Botany, New South Wales 2019, Australia
  • The Rheumatology Research Unit Sunshine Coast
    Maroochydore, Queensland 4558, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • St Vincents Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • Griffith University
    Southport, 4215, Australia
  • Ordensklinikum Linz GmbH Elisabethinen
    Linz, Oberösterreich 4020, Austria
  • Medizinische Universität Graz
    Graz, 8036, Austria
  • Klinik Hietzing
    Wien, 1130, Austria
  • Cliniques Universitaires Saint-Luc
    Bruxelles, Brussel 1200, Belgium
  • UZ Leuven
    Leuven, Vlaams Brabant 3000, Belgium
  • CHU de Liège
    Liège, 4000, Belgium
  • SER - Serviços Especializados em Reumatologia da Bahia S/S - ME
    Salvador, Bahia 40150-150, Brazil
  • CIP-Centro Internacional de Pesquisa
    Goiania, Goiás 74110-120, Brazil
  • Santa Casa de Misericordia de Belo Horizonte
    Belo Horizonte, MG 30150-221, Brazil
  • Centro de Estudos em Terapias Inovadoras-CETI
    Curitiba, Paraná 80030-110, Brazil
  • EDUMED - Educação em Saúde Ltda.
    Curitiba, Paraná 80440-080, Brazil
  • LMK Serviços Médicos S/S
    Porto Alegre, Rio Grande Do Sul 90540-000, Brazil
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, RS 90035-003, Brazil
  • Hospital de Clinicas UNICAMP
    Campinas, SP 13083-970, Brazil
  • Oncovida- Centro de Onco-Hematologia de Mato Grosso
    Cuiaba, 78043-142, Brazil
  • Hospital Alemao Oswaldo Cruz
    Sao Paulo, 01323-903, Brazil
  • First affiliated Hospital of Sun Yat-Sen University
    Guangzhou, Guangdong 510080, China
  • First Affiliated Hospital of the Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • The First Affiliated Hospital of Zhengzhou Universtiy
    Zhengzhou, Henan 450000, China
  • Wuhan Union Hospital
    Wuhan, Hubei 430022, China
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210000, China
  • Jiangxi Pingxiang People's Hospital
    Pingxiang, Jiangxi 337055, China
  • China-Japan Union Hospital of Jilin University
    Changchun, Jilin 100853, China
  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai 200032, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
  • Ningbo First Hospital
    Ningbo, Zhejiang 315010, China
  • Peking University First Hospital
    Beijing, 100034, China
  • Beijing Peking Union Medical College Hospital
    Beijing, 100730, China
  • Shanghai Huashan Hospital Affil to Fu Dan University
    Shanghai, 200040, China
  • China Medical University (CMU) - First Affiliated Hospital
    Shenyang, 110001, China
  • The First Affliated Hospital of Soochow University
    Suzhou Shi, 215000, China
  • People's Hospital of Xinjiang Uygur Autonomous Region
    Urumqi, 830001, China
  • Klinicki Bolnicki Centar Rijeka
    Rijeka, 51000, Croatia

Showing the first 100 of 184 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. PubMed 33687069 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · trials.lillytrialguide.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Nov 2021, 38 months.

Results were first posted in Jan 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2018
First posted
Aug 6, 2018
StartActual
Aug 2, 2018
Primary completionActual
Nov 1, 2021
CompletionActual
Mar 9, 2022
Results first posted
Jan 30, 2023
Last update
Jan 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03616912
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Aug 6, 2018
Start date
Aug 2, 2018
Primary completion
Nov 1, 2021
Completion
Mar 9, 2022
Results posted
Jan 30, 2023
Last update
Jan 30, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion